Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    48,554.72
    -1,729.62 (-3.44%)
     
  • CMC Crypto 200

    1,260.80
    -97.21 (-7.16%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

GSK signs $196 mln U.S. anthrax treatment deal

LONDON, Sept 19 (Reuters) - Britain's GlaxoSmithkline (LSE: GSK.L - news) said it had signed a new four-year deal worth $196 million to supply the U.S. government with its inhalation anthrax treatment, raxibacumab, in case of a potential bio-terrorist attack.

GSK said on Thursday that it would supply 60,000 doses of the treatment to the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services.